- Home
- WOLF vs REPL Comparison
WOLF vs REPL Comparison
Compare WOLF & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- REPL
- Stock Information
- Founded
- WOLF 1987
- REPL 2015
- Country
- WOLF United States
- REPL United States
- Employees
- WOLF N/A
- REPL N/A
- Industry
- WOLF Semiconductors
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- REPL Health Care
- Exchange
- WOLF Nasdaq
- REPL Nasdaq
- Market Cap
- WOLF 978.5M
- REPL 851.0M
- IPO Year
- WOLF 1993
- REPL 2018
- Fundamental
- Price
- WOLF $3.05
- REPL $9.75
- Analyst Decision
- WOLF Hold
- REPL Strong Buy
- Analyst Count
- WOLF 16
- REPL 6
- Target Price
- WOLF $14.86
- REPL $20.00
- AVG Volume (30 Days)
- WOLF 29.1M
- REPL 658.1K
- Earning Date
- WOLF 04-30-2025
- REPL 05-15-2025
- Dividend Yield
- WOLF N/A
- REPL N/A
- EPS Growth
- WOLF N/A
- REPL N/A
- EPS
- WOLF N/A
- REPL N/A
- Revenue
- WOLF $776,600,000.00
- REPL N/A
- Revenue This Year
- WOLF N/A
- REPL $31.16
- Revenue Next Year
- WOLF $31.88
- REPL N/A
- P/E Ratio
- WOLF N/A
- REPL N/A
- Revenue Growth
- WOLF N/A
- REPL N/A
- 52 Week Low
- WOLF $2.41
- REPL $4.92
- 52 Week High
- WOLF $30.86
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- WOLF 32.47
- REPL 28.07
- Support Level
- WOLF $5.46
- REPL $10.17
- Resistance Level
- WOLF $6.68
- REPL $10.78
- Average True Range (ATR)
- WOLF 0.58
- REPL 0.62
- MACD
- WOLF -0.27
- REPL -0.12
- Stochastic Oscillator
- WOLF 14.99
- REPL 5.56
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.